# A Clinical Trial Evaluating the Safety of Hydronidone Capsules in Patients With Hepatic Fibrosis and Liver Cirrhosis

> **NCT07343778** · PHASE3 · RECRUITING · sponsor: **Beijing Continent Pharmaceutical Co, Ltd.** · enrollment: 300 (estimated)

## Conditions studied

- Chronic Hepatitis B With Hepatic Fibrosis

## Interventions

- **DRUG:** Hydronidone Capsules

## Key facts

- **NCT ID:** NCT07343778
- **Lead sponsor:** Beijing Continent Pharmaceutical Co, Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-03-16
- **Primary completion:** 2026-10-30
- **Final completion:** 2026-10-30
- **Target enrollment:** 300 (ESTIMATED)
- **Last updated:** 2026-03-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07343778

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07343778, "A Clinical Trial Evaluating the Safety of Hydronidone Capsules in Patients With Hepatic Fibrosis and Liver Cirrhosis". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT07343778. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*